BMS-986218

BIOLOGICAL2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced CancerProstatic Neoplasms, Castration-Resistant

Phase 1

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

TerminatedNCT03110107

Bristol-Myers SquibbAdvanced Cancer

Start: 2017-05-04End: 2024-04-04Updated: 2025-04-24

Phase 2

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

TerminatedNCT05169684

Bristol-Myers SquibbProstatic Neoplasms, Castration-Resistant

Start: 2022-02-14End: 2023-12-06Updated: 2025-06-10

Related Papers

592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results

Regular and Young Investigator Award Abstracts2022-11-012 citations

393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

Regular and Young Investigator Award Abstracts2020-11-019 citations

Abstract 4552: Preclinical characterization of BMS-986218, a novel nonfucosylated anti–CTLA-4 antibody designed to enhance antitumor activity

Cancer Research2020-08-1511 citations

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Journal for ImmunoTherapy of Cancer2020-06-0166 citations